ClinicalTrials.gg
TerminatedNCT04577183Updated Dec 2, 2024Results posted

A Prospective, Open Label, Multicenter Trial for Evaluating the Efficacy of Treating and Managing Wounds in Elderly Population in Specialized Nursing Facilities Using RD1

An interventional study of RD1 System in Diabetic Foot Ulcer, Pressure Ulcer and Venous Leg Ulcer, sponsored by RedDress Ltd.. Terminated at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2024-12-02.

Sponsored by RedDress Ltd. · Not applicable, Interventional, and Treatment

How we know

Why this study was terminated
operational challenges

From the registry’s dates

  • Registered 8 months after the study started (first participant enrolled Jul 2018, registered Mar 2019).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
13
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 381 studies in Diabetic Foot with a site in United States — 66 open to participants now, 84 under way, 3 of them phase 3. Diabetic Foot · United States.

Enrollment
275th of 322
13 · median 60
Started
2018
with 13 others
No phase
186 of 381
38 open now
Registered
206th of 381
by date

Among the 381 studies in Diabetic Foot with a site in United States, this one is the 275th largest by enrollment of the 322 interventional ones that give a count, is one of 14 that started in 2018, is one of 186 with no phase, and was the 206th registered.

Diabetic Foot

1,079 studies on the registry are indexed under Diabetic Foot; 221 are open to participants now.

Browse Diabetic Foot studies →

Open to participants now

66 of the 381 studies in Diabetic Foot with a site in United States are open now. Recruiting first, the newest first:

61 more — sign in →

All 66 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 139 Diabetic Foot studies recruiting now, 98 (71%) set no upper age limit and 12 (9%) stop at 75 or younger; 5 take children under 18; 11 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 381 studies in Diabetic Foot with a site in United States, or all of them as a file.
02

Study summary

The study is a prospective, single arm, multicenter efficacy study, consisting of 60 subjects who will complete the study (note: if any patients are lost to follow-up or withdrawn, enrollment will increase to compensate for loss of these subjects). The subjects will receive up to 16 RD1 applications. In case of complete healing, subject will be called for one confirmatory visit two weeks later or before discharge from the SNF (the earlier of the two). Subject data will be kept in each site's records.

All diabetic subjects' glycemic management will be performed by a qualified physician. All subjects will have wound care specialist or wound surgeon or dermatologist involved in their wound care

03

Conditions studied

  • Diabetic Foot Ulcer
  • Pressure Ulcer
  • Venous Leg Ulcer
  • Trauma Injury
  • Skin Tear
  • Chronic Ulcer
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Subject is ≥18 years of age
  • Patient with a wound deemed suitable for treatment with RD1
  • Ulcer free of clinical signs of infection.
  • Post-debridement, ulcer free of necrotic tissue.
  • For foot ulcers, Subject has adequate vascular perfusion of the affected limb, as defined by - Ankle-Brachial Index (ABI) ≥ 0.65 and ≤ 1.2
  • ≤ 12.0% (diabetic patients)
  • Subject or legal authorized representative must be willing to comply with the protocol including having blood drawn to create the RD1.
  • Female subjects who are capable of conceiving must use an acceptable form of in order to participate in the study (acceptable forms of contraception include condoms for males and contraceptive pills or IUDs for women).

Exclusion criteria

Exclusion Criteria:

  • If ulcer area decreases by ≥ 30% during the initial 2-week screening (± 2 days) and standard of care phase, or if the ulcer area increases ≥ 30%,
  • Presence of active underlying osteomyelitis.
  • Patient with a proven sepsis established by a blood culture in the past 2 weeks, or confirmed active infection likely to interfere with trial, such as urine tract infection
  • Known in the reference wound bed or margins of the wound
  • Exposure of blood vessels or organs at the base of the reference wound
  • History of alcohol or substance abuse, within the previous 2 months
  • Subject has participated in another clinical trial involving a device or a systemically administered study drug or treatment within 30 days of day 0 visit.
  • Subject is currently receiving (i.e., within the past 30 days) or scheduled to receive a medication or treatment which, in the opinion of the Investigator, is known to interfere with, or affect the rate and quality of, wound healing (e.g., systemic (more than 10mg per day), therapy, disease therapy, cytostatic therapy within the past 12 months, dialysis, radiation therapy to the ulcer area, vascular surgery, angioplasty or thrombolysis).
  • Subject has been treated with wound dressings that include growth factors, engineered tissues or skin substitutes within 30 days of randomization or is scheduled to receive during the study.
  • Subject has been treated with hyperbaric oxygen within 5 days of screening or is scheduled to receive during the study.
  • Wound on a patient who has a of less than 6 months.
  • Cannot withdraw blood in the required amount technically.
  • Known coagulation problems, abnormal level or if heparin is given intravenously. Patients who are taking orally Coumadin, Aspirin, or Plavix (clopidogrel) will not be excluded.
  • anemia (\< 9 g/dL).
  • Subject has an infectious disease, such as Acquired Immune Deficiency Disease (AIDS) or , , , Human T-lymphotropic virus or Syphilis
  • Women who are pregnant or currently breast feeding.
Terms in these criteria, in plain language(13)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
13 participants (actual)

Study arms

  • Experimental
    RD1 System

    The RD1 is created by drawing the patient's blood with the use of citrate anticoagulant. The anticoagulant allows the clot to form later in a controlled fashion-citrate is a widely used anticoagulant. The blood is then placed in the clotting tray (within few minutes) and the coagulation is facilitated by adding calcium and kaolin (insoluble aluminum silicate). The forming clot assumes the shape of the tray containing it, and can then be applied to the wound, and then covered with primary and secondary dressings.

    Device: RD1 System

Interventions

  • DeviceRD1 System

    The RD1 is created by drawing the patient's blood with the use of citrate anticoagulant. The anticoagulant allows the clot to form later in a controlled fashion-citrate is a widely used anticoagulant. The blood is then placed in the clotting tray (within few minutes) and the coagulation is facilitated by adding calcium and kaolin (insoluble aluminum silicate). The forming clot assumes the shape of the tray containing it, and can then be applied to the wound, and then covered with primary and secondary dressings.

06

What researchers measure

Primary outcomes

  1. Number of Participants With Reduction in Wound Size

    Numer of patients showed Percent of wound reduction from baseline to end of treatment in the intent to treat (ITT) population

    Time frame: 16 weeks

07

Results

Posted May 13, 2021
Limitations and caveats
The study had a Statistical Analysis Plan in progress that wasn't finalized. Due to the small group size, conclusions could be made without conducting statistics for the study population.

Participant flow

Participant flow — Overall Study
MilestoneRD1 System
Started13
Completed7
Not completed6
Withdrew: Death1
Withdrew: Withdrawal by subject3
Withdrew: Early termination2

Outcome measures

PrimaryNumber of Participants With Reduction in Wound Size

Numer of patients showed Percent of wound reduction from baseline to end of treatment in the intent to treat (ITT) population

Time frame:
16 weeks
Reported as:
Number · participants with Wound Size reduction
Number of Participants With Reduction in Wound Size
participants with Wound Size reductionRD1 System
Number of Participants With Reduction in Wound Size7

Adverse events

Collected over 16 weeks. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
RD1 System1/13 (7.7%)1/13 (7.7%)5/13 (38.5%)
Most frequent serious events
Most frequent serious events
EventRD1 System
DeathCardiac disorders1/13
Most frequent other events
Most frequent other events
EventRD1 System
Multiple fluid filled blisters to left lower extrimityMusculoskeletal and connective tissue disorders1/13
Open area on right upper shinMusculoskeletal and connective tissue disorders1/13
CellulitisMusculoskeletal and connective tissue disorders1/13
FeverGeneral disorders1/13
Skin tearSkin and subcutaneous tissue disorders1/13
New ulcerSkin and subcutaneous tissue disorders1/13
Infection to study ulcerInfections and infestations1/13

Baseline characteristics

Age, Categorical
Age, Categorical(Participants)RD1 System
<=18 years0
Between 18 and 65 years0
>=65 years13
Sex: Female, Male
Sex: Female, Male(Participants)RD1 System
Female7
Male6
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)RD1 System
Hispanic or Latino0
Not Hispanic or Latino13
Unknown or Not Reported0
08

Study locations

1 site
  • Sunnyview Nursing & Rehabilitation Center
    Butler, Pennsylvania 16001, United States
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Jul 2018 to primary completion in Feb 2019, 6 months.

Results were first posted in May 2021, 2 years 3 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 20, 2019
First posted
Oct 6, 2020
StartActual
Jul 11, 2018
Primary completionActual
Feb 1, 2019
CompletionActual
Feb 1, 2019
Results first posted
May 13, 2021
Last update
Dec 2, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 2, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT04577183
Lead sponsor
RedDress Ltd.
Responsible party
Sponsor
First posted
Oct 6, 2020
Start date
Jul 11, 2018
Primary completion
Feb 1, 2019
Completion
Feb 1, 2019
Results posted
May 13, 2021
Last update
Dec 2, 2024

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Nov 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion